vs
EXACT SCIENCES CORP（EXAS）与Primo Brands Corp（PRMB）财务数据对比。点击上方公司名可切换其他公司
Primo Brands Corp的季度营收约是EXACT SCIENCES CORP的1.8倍（$1.6B vs $878.4M），Primo Brands Corp净利率更高（-0.8% vs -9.8%，领先8.9%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $57.3M）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Primo Brands Corp是一家美加合资饮用水企业，主营多规格桶装水、饮水机、自助补水设备及净水家电，总部位于美国佛罗里达州坦帕市，服务覆盖美国、加拿大、欧洲及以色列的住宅与商业客户。
EXAS vs PRMB — 直观对比
营收规模更大
PRMB
是对方的1.8倍
$878.4M
净利率更高
PRMB
高出8.9%
-9.8%
自由现金流更多
EXAS
多$63.1M
$57.3M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.6B |
| 净利润 | $-86.0M | $-13.0M |
| 毛利率 | 70.1% | 27.7% |
| 营业利润率 | -9.4% | 1.2% |
| 净利率 | -9.8% | -0.8% |
| 营收同比 | 23.1% | — |
| 净利润同比 | 90.1% | — |
| 每股收益（稀释后） | $-0.45 | $-0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASPRMB
| Q4 25 | $878.4M | $1.6B | ||
| Q3 25 | $850.7M | $1.8B | ||
| Q2 25 | $811.1M | $1.7B | ||
| Q1 25 | $706.8M | $1.6B | ||
| Q4 24 | $713.4M | — | ||
| Q3 24 | $708.7M | $0 | ||
| Q2 24 | $699.3M | $1.3B | ||
| Q1 24 | $637.5M | $1.1B |
净利润EXASPRMB
| Q4 25 | $-86.0M | $-13.0M | ||
| Q3 25 | $-19.6M | $16.8M | ||
| Q2 25 | $-1.2M | $27.6M | ||
| Q1 25 | $-101.2M | $28.7M | ||
| Q4 24 | $-864.6M | — | ||
| Q3 24 | $-38.2M | $-2.0K | ||
| Q2 24 | $-15.8M | $54.5M | ||
| Q1 24 | $-110.2M | $33.5M |
毛利率EXASPRMB
| Q4 25 | 70.1% | 27.7% | ||
| Q3 25 | 68.6% | 29.9% | ||
| Q2 25 | 69.3% | 31.3% | ||
| Q1 25 | 70.8% | 32.3% | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | 32.7% | ||
| Q1 24 | 70.0% | 30.4% |
营业利润率EXASPRMB
| Q4 25 | -9.4% | 1.2% | ||
| Q3 25 | -3.0% | 8.3% | ||
| Q2 25 | -0.3% | 6.5% | ||
| Q1 25 | -13.6% | 9.5% | ||
| Q4 24 | -122.8% | — | ||
| Q3 24 | -5.6% | — | ||
| Q2 24 | -3.8% | 12.1% | ||
| Q1 24 | -16.7% | 11.0% |
净利率EXASPRMB
| Q4 25 | -9.8% | -0.8% | ||
| Q3 25 | -2.3% | 1.0% | ||
| Q2 25 | -0.1% | 1.6% | ||
| Q1 25 | -14.3% | 1.8% | ||
| Q4 24 | -121.2% | — | ||
| Q3 24 | -5.4% | — | ||
| Q2 24 | -2.3% | 4.1% | ||
| Q1 24 | -17.3% | 2.9% |
每股收益（稀释后）EXASPRMB
| Q4 25 | $-0.45 | $-0.03 | ||
| Q3 25 | $-0.10 | $0.04 | ||
| Q2 25 | $-0.01 | $0.07 | ||
| Q1 25 | $-0.54 | $0.08 | ||
| Q4 24 | $-4.69 | — | ||
| Q3 24 | $-0.21 | $-20.00 | ||
| Q2 24 | $-0.09 | $0.25 | ||
| Q1 24 | $-0.60 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $376.7M |
| 总债务越低越好 | — | $5.2B |
| 股东权益账面价值 | $2.4B | $3.0B |
| 总资产 | $5.9B | $10.6B |
| 负债/权益比越低杠杆越低 | — | 1.72× |
8季度趋势，按日历期对齐
现金及短期投资EXASPRMB
| Q4 25 | $964.7M | $376.7M | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $858.4M | — | ||
| Q1 25 | $786.2M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $946.8M | — | ||
| Q1 24 | $652.1M | — |
总债务EXASPRMB
| Q4 25 | — | $5.2B | ||
| Q3 25 | — | $5.1B | ||
| Q2 25 | — | $5.1B | ||
| Q1 25 | — | $5.0B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EXASPRMB
| Q4 25 | $2.4B | $3.0B | ||
| Q3 25 | $2.5B | $3.2B | ||
| Q2 25 | $2.5B | $3.2B | ||
| Q1 25 | $2.4B | $3.3B | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $3.2B | $-2.0K | ||
| Q2 24 | $3.2B | $-296.8M | ||
| Q1 24 | $3.1B | $-349.8M |
总资产EXASPRMB
| Q4 25 | $5.9B | $10.6B | ||
| Q3 25 | $5.9B | $11.0B | ||
| Q2 25 | $5.8B | $11.0B | ||
| Q1 25 | $5.7B | $11.0B | ||
| Q4 24 | $5.9B | — | ||
| Q3 24 | $6.7B | $0 | ||
| Q2 24 | $6.7B | — | ||
| Q1 24 | $6.4B | — |
负债/权益比EXASPRMB
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | 1.61× | ||
| Q2 25 | — | 1.57× | ||
| Q1 25 | — | 1.51× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $203.1M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $57.3M |
| 自由现金流率自由现金流/营收 | 13.7% | 3.7% |
| 资本支出强度资本支出/营收 | 3.6% | 9.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $302.9M |
8季度趋势，按日历期对齐
经营现金流EXASPRMB
| Q4 25 | $151.7M | $203.1M | ||
| Q3 25 | $219.9M | $283.4M | ||
| Q2 25 | $89.0M | $155.0M | ||
| Q1 25 | $30.8M | $38.8M | ||
| Q4 24 | $47.1M | — | ||
| Q3 24 | $138.7M | $0 | ||
| Q2 24 | $107.1M | $102.5M | ||
| Q1 24 | $-82.3M | $6.0M |
自由现金流EXASPRMB
| Q4 25 | $120.4M | $57.3M | ||
| Q3 25 | $190.0M | $167.7M | ||
| Q2 25 | $46.7M | $101.1M | ||
| Q1 25 | $-365.0K | $-23.2M | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | $61.4M | ||
| Q1 24 | $-120.0M | $-17.5M |
自由现金流率EXASPRMB
| Q4 25 | 13.7% | 3.7% | ||
| Q3 25 | 22.3% | 9.5% | ||
| Q2 25 | 5.8% | 5.8% | ||
| Q1 25 | -0.1% | -1.4% | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | 4.7% | ||
| Q1 24 | -18.8% | -1.5% |
资本支出强度EXASPRMB
| Q4 25 | 3.6% | 9.4% | ||
| Q3 25 | 3.5% | 6.6% | ||
| Q2 25 | 5.2% | 3.1% | ||
| Q1 25 | 4.4% | 3.8% | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | 3.1% | ||
| Q1 24 | 5.9% | 2.1% |
现金转化率EXASPRMB
| Q4 25 | — | — | ||
| Q3 25 | — | 16.87× | ||
| Q2 25 | — | 5.62× | ||
| Q1 25 | — | 1.35× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.88× | ||
| Q1 24 | — | 0.18× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
PRMB
| Regional Spring Water | $765.1M | 49% |
| Purified Water | $484.5M | 31% |
| Other | $188.4M | 12% |
| Premium Water | $90.3M | 6% |
| Other Water | $25.8M | 2% |
